LENTIVIRAL-MEDIATED EX-VIVO GENE THERAPY FOR PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I): INTERIM RESULTS FROM AN ONGOING PHASE 1/2 STUDY

被引：0

作者：

Kohn, Donald ^{[1
]}

Sevilla, Julian ^{[2
,3
]}

Rao, Gayatri ^{[4
]}

Lopez, Maria Chitty ^{[4
]}

Almarza, Elena ^{[4
]}

Terrazas, Dayna ^{[1
]}

Zubicaray, Josune ^{[2
,3
]}

Gonzalez-Vicent, Marta ^{[2
,3
]}

Chetty, Kritika ^{[5
]}

O'Toole, Grainne ^{[5
]}

Xu-Bayford, Jinhua ^{[5
]}

Nicoletti, Eileen ^{[4
]}

Fernandes, Augustine ^{[1
]}

Kuo, Caroline ^{[1
]}

De Oliveira, Satiro ^{[1
]}

Moore, Theodore B. ^{[1
]}

Choi, Grace ^{[4
]}

Zeini, Miriam ^{[4
]}

Mesa-Nunez, Cristina ^{[4
]}

Thrasher, Adrian ^{[5
]}

Bueren, Juan ^{[3
,6
]}

Schwartz, Jonathan ^{[4
,7
]}

Booth, Claire ^{[5
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Hosp Infantil Univ Nino Jesus HIUNJ, Fdn Invest Biomed, Madrid, Spain

[3] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain

[4] Rocket Pharmaceut Inc, Cranbury, NJ USA

[5] UCL Great Ormond St Inst Child Hlth, London, England

[6] Ctr Invest Energet Medioambient & Tecnol CIEMAT, Madrid, Spain

[7] Inst Invest Sanitaria Fdn Jimenez Diaz IIS FJD, Madrid, Spain

来源：

BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O061

引用

页码：61 / 62

页数：2

共 50 条

[41] A PHASE 1/2 CLINICAL TRIAL FOR AAV8-MEDIATED LIVER-DIRECTED GENE THERAPY IN ADULTS WITH LATE-ONSET OTC DEFICIENCY: INTERIM RESULTS FROM COHORT 1
Harding, Cary O.
Geberhiwot, Tarekegn
Aldamiz-Echevarria, Luis
Luz Couce, Maria
Khan, Aneal
Tan, Wen-Hann
Crombez, Eric
Diaz, George A.
MOLECULAR GENETICS AND METABOLISM, 2019, 127 (03) : 240 - 240
[42] EFFICACY AND SAFETY OF MIRIKIZUMAB THERAPY IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDY
Kaplan, Jess
Bousvaros, Athos
Turner, Dan
Dubinsky, Marla C.
Komocsar, Wendy
Larkin, Amy E.
Johns, Jordan
Zhang, Xin
Crandall, Wallace
Arora, Vipin
Todd, Kris
Hyams, Jeffrey S.
GASTROENTEROLOGY, 2024, 166 (05) : S819 - S820
[43] Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
Kanter, Julie
Walters, Mark C.
Hsieh, Matthew
Thompson, Alexis A.
Krishnamurti, Lakshmanan
Kwiatkowski, Janet
Kamble, Rammurti T.
von Kalle, Christof
Kuypers, Frans A.
Cavazzana, Marina
Leboulch, Philippe
Sandler, Laura
Soni, Sandeep
Tisdale, John F.
BLOOD, 2015, 126 (23)
[44] Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product)
Walters, Mark C.
Rasko, John
Hongeng, Suradej
Kwiatkowski, Janet
Schiller, Gary J.
Kletzel, Morris
Ho, P. Joy
Vichinsky, Elliott
von Kalle, Christof
Cavazzana, Marina
Leboulch, Philippe
Petrusich, Alexandria
Soni, Sandeep
Thompson, Alexis A.
BLOOD, 2015, 126 (23)
[45] Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene
Lal, Ashutosh
Locatelli, Franco
Kwiatkowski, Janet L.
Kulozik, Andreas E.
Yannaki, Evangelia
Porter, John B.
Thuret, Isabelle
Sauer, Martin G.
Elliot, Heidi
Chen, Ying
Colvin, Richard A.
Thompson, Alexis A.
BLOOD, 2019, 134
[46] Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Kelly, W.
Danila, D.
Lin, C-C.
Lee, J-L.
Matsubara, N.
Ward, P.
Armstrong, A. J.
Pook, D.
Kim, M.
Dorff, T.
Fischer, S.
Lin, Y-C.
Horvath, L. G.
Sumey, C.
Yang, Z.
Jurida, G.
Connarn, J.
Penny, H.
Stieglmaier, J.
Appleman, L. J.
ANNALS OF ONCOLOGY, 2023, 34 : S953 - S954
[47] Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Kelly, W. K.
Danila, D. C.
Lin, C-C.
Lee, J-L.
Matsubara, N.
Ward, P. J.
Armstrong, A. J.
Pook, D. W.
Kim, M.
Dorff, T.
Fischer, S.
Lin, Y-C.
Horvath, L. G.
Sumey, C.
Yang, Z.
Jurida, G.
Connarn, J.
Penny, H.
Stieglmaier, J.
Appleman, L. J.
ANNALS OF ONCOLOGY, 2023, 34 : S1576 - S1576
[48] Interim results from a phase I/II study of duvelisib PI3Kdg inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
Jin, Jingxiao
Rohatgi, Anjali
Gabrielle, Andrew
Rose, Amy
Wilson, Melissa
Bruno, Tullia C.
Kirkwood, John M. M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral βA-T87Q Globin Vector (LentiGlobin BB305 Drug Product)
Thompson, Alexis A.
Rasko, John E.
Hongeng, Suradej
Kwiatkowski, Janet L.
Schiller, Gary
von Kalle, Christof
Cavazzana, Marina
Leboulch, Philippe
Petrusich, Alexandria
Soni, Sandeep
Walters, Mark C.
BLOOD, 2014, 124 (21)
[50] Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma
Kawai, Akira
Ishihara, Mikiya
Nakamura, Tomoki
Kitano, Shigehisa
Iwata, Shintaro
Takada, Kohichi
Emori, Makoto
Kato, Koji
Endo, Makoto
Matsumoto, Yoshihiro
Kakunaga, Shigeki
Sato, Eiichi
Miyahara, Yoshihiro
Morino, Kunihiko
Tanaka, Shinya
Takahashi, Shuichi
Matsumine, Akihiko
Kageyama, Shinichi
Ueda, Takafumi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →